Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY2801653 + cisplatin
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**LY2801653 + cisplatin** is an investigational combination therapy involving merestinib (LY2801653), a potent, orally bioavailable, small-molecule multi-kinase inhibitor targeting MET, MST1R (RON), and other receptor tyrosine kinases, and cisplatin, a platinum-based chemotherapy agent. Merestinib inhibits MET signaling, which is implicated in tumor growth, metastasis, and resistance to therapy, and is being evaluated in combination with cisplatin—an agent that induces DNA crosslinks and damage, leading to apoptosis—in various solid tumors, especially advanced or metastatic biliary tract cancer. The combination has shown tolerable safety and anti-tumor activity in early phase clinical studies in advanced cancers[2][5][6].
- Other names
- merestinib + cisplatin
02
Targets
AXL (AXL receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TEK (Angiopoietin-1 receptor)MKNK2 (MAP kinase-interacting serine/threonine-protein kinase 2)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)MKNK1 (Mitogen‑activated protein kinase‑interacting serine/threonine-protein kinase 1)MST1R (Recepteur d'origine nantais)DDR1 (Discoidin domain receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)DDR2 (Discoidin domain receptor tyrosine kinase 2)
Beyond the preview
Go deeper on LY2801653 + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY2801653 + cisplatin.